Jun 29, 2020

Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders.  Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and...

Jun 29, 2020

Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders.  Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and...

Jun 25, 2020

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer.  The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight...

Jun 25, 2020

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer.  The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight...

Jun 24, 2020

Mike Clayman, M.D., Chief Executive Officer and Co-Founder, Flexion Therapeutics brings us up to speed on the work at Flexion developing and commercializing new treatments for musculoskeletal disorders (MSDs) including osteoarthritis (OA) knee pain. Mike also talks about how the company has been adapting to the COVID-19...